• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫调节剂FTY720通过溶血磷脂受体S1P3和Smad3信号通路诱导肌成纤维细胞分化。

Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling.

作者信息

Keller Christina D, Rivera Gil Pilar, Tölle Markus, van der Giet Markus, Chun Jerold, Radeke Heinfried H, Schäfer-Korting Monika, Kleuser Burkhard

机构信息

Institute of Pharmacy, Pharmacology and Toxicology, Freie Universität Berlin, Königin-Luise-Str. 2+4, D-14195 Berlin, Germany.

出版信息

Am J Pathol. 2007 Jan;170(1):281-92. doi: 10.2353/ajpath.2007.060485.

DOI:10.2353/ajpath.2007.060485
PMID:17200201
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1762708/
Abstract

The novel immunomodulator FTY720 is an effective immunosuppressive agent in experimental models of transplantation and autoimmunity and is currently undergoing phase III clinical trials for multiple sclerosis. Phosphorylated FTY720 is a structural analogue of sphingosine 1-phosphate (S1P) and therefore acts as a high-affinity agonist at four of the five G protein-coupled S1P receptors. It has been well established that there exists a crosstalk between S1P and transforming growth factor (TGF)-beta signaling. Because TGF-beta is the most prominent inductor of fibrosis and myofibroblasts are primarily responsible for excessive matrix protein formation, we examined whether FTY720, in analogy to TGF-beta, induces differentiation of fibroblasts into myofibroblasts. Indeed, FTY720 provoked myofibroblast differentiation comparable with that of TGF-beta. For biological efficacy, FTY720 required endogenous phosphorylation because inhibition of sphingosine kinase completely prevented FTY720 from inducing the differentiation process. Moreover, we identified the lysophospholipid receptor S1P3 as the crucial receptor subtype for FTY720-induced myofibroblast differentiation because the effect was abolished in fibroblasts isolated from S1P3 knockout mice. Finally, we determined that downstream of S1P3 signaling Smad3 activation is essential for myofibroblast differentiation in response to FTY720. Thus, FTY720 may have adverse fibrotic effects related to its activity on S1P3 signaling.

摘要

新型免疫调节剂FTY720在移植和自身免疫的实验模型中是一种有效的免疫抑制剂,目前正在进行针对多发性硬化症的III期临床试验。磷酸化的FTY720是1-磷酸鞘氨醇(S1P)的结构类似物,因此在五个G蛋白偶联的S1P受体中的四个上作为高亲和力激动剂起作用。S1P与转化生长因子(TGF)-β信号传导之间存在相互作用,这一点已经得到充分证实。由于TGF-β是纤维化最主要的诱导因子,而成肌纤维细胞主要负责过多的基质蛋白形成,我们研究了FTY720是否与TGF-β类似,诱导成纤维细胞分化为成肌纤维细胞。事实上,FTY720引发的成肌纤维细胞分化与TGF-β相当。为了产生生物学效应,FTY720需要内源性磷酸化,因为抑制鞘氨醇激酶完全阻止了FTY720诱导分化过程。此外,我们确定溶血磷脂受体S1P3是FTY720诱导成肌纤维细胞分化的关键受体亚型,因为从S1P3基因敲除小鼠分离的成纤维细胞中该效应消失。最后,我们确定在S1P3信号传导下游,Smad3激活对于响应FTY720的成肌纤维细胞分化至关重要。因此,FTY720可能因其对S1P3信号传导的活性而具有不良的纤维化作用。

相似文献

1
Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling.免疫调节剂FTY720通过溶血磷脂受体S1P3和Smad3信号通路诱导肌成纤维细胞分化。
Am J Pathol. 2007 Jan;170(1):281-92. doi: 10.2353/ajpath.2007.060485.
2
Immunomodulator FTY720 Induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3.免疫调节剂FTY720通过溶血磷脂受体S1P3诱导内皮型一氧化氮合酶依赖的动脉血管舒张。
Circ Res. 2005 Apr 29;96(8):913-20. doi: 10.1161/01.RES.0000164321.91452.00. Epub 2005 Mar 31.
3
Sphingosine 1-phosphate (S1P) receptor agonists mediate pro-fibrotic responses in normal human lung fibroblasts via S1P2 and S1P3 receptors and Smad-independent signaling.鞘氨醇 1-磷酸(S1P)受体激动剂通过 S1P2 和 S1P3 受体和非 Smad 依赖性信号通路介导正常肺成纤维细胞的促纤维化反应。
J Biol Chem. 2013 May 24;288(21):14839-51. doi: 10.1074/jbc.M112.426726. Epub 2013 Apr 15.
4
The immunomodulator FTY720 and its phosphorylated derivative activate the Smad signalling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells.免疫调节剂FTY720及其磷酸化衍生物可激活Smad信号级联反应,并上调肾系膜细胞中结缔组织生长因子和IV型胶原的表达。
Br J Pharmacol. 2006 Jan;147(2):164-74. doi: 10.1038/sj.bjp.0706452.
5
Phosphorylation of the immunomodulator FTY720 inhibits programmed cell death of fibroblasts via the S1P3 receptor subtype and Bcl-2 activation.免疫调节剂FTY720的磷酸化通过S1P3受体亚型和Bcl-2激活抑制成纤维细胞的程序性细胞死亡。
Cell Physiol Biochem. 2010;26(1):67-78. doi: 10.1159/000315107. Epub 2010 May 18.
6
FTY720 modulates human oligodendrocyte progenitor process extension and survival.FTY720调节人少突胶质前体细胞的突起延伸和存活。
Ann Neurol. 2008 Jan;63(1):61-71. doi: 10.1002/ana.21227.
7
Smad3 deficiency leads to mandibular condyle degradation via the sphingosine 1-phosphate (S1P)/S1P3 signaling axis.Smad3 缺失通过鞘氨醇 1-磷酸(S1P)/S1P3 信号轴导致下颌骨髁突降解。
Am J Pathol. 2015 Oct;185(10):2742-56. doi: 10.1016/j.ajpath.2015.06.015. Epub 2015 Aug 10.
8
Cross-talk between PDGF and S1P signalling elucidates the inhibitory effect and potential antifibrotic action of the immunomodulator FTY720 in activated HSC-cultures.血小板衍生生长因子(PDGF)与鞘氨醇-1-磷酸(S1P)信号通路之间的相互作用阐明了免疫调节剂FTY720在活化的肝星状细胞培养物中的抑制作用及潜在的抗纤维化作用。
Biochim Biophys Acta. 2008 Mar;1783(3):347-59. doi: 10.1016/j.bbamcr.2007.11.008. Epub 2007 Nov 29.
9
FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.FTY720(芬戈莫德)在多发性硬化症动物模型中的疗效需要星形胶质细胞鞘氨醇 1-磷酸受体 1(S1P1)的调节。
Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):751-6. doi: 10.1073/pnas.1014154108. Epub 2010 Dec 21.
10
Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor.鞘氨醇-1-磷酸通过S1P3受体激活CXCR4依赖性信号通路,刺激祖细胞的功能能力。
Arterioscler Thromb Vasc Biol. 2007 Feb;27(2):275-82. doi: 10.1161/01.ATV.0000254669.12675.70. Epub 2006 Dec 7.

引用本文的文献

1
A guided journey through the pathophysiology of pulmonary hypertension-from measured metabolites to the mechanism of action of drugs.肺动脉高压病理生理学的引导之旅——从测量的代谢物到药物作用机制
Front Cardiovasc Med. 2024 May 23;11:1341145. doi: 10.3389/fcvm.2024.1341145. eCollection 2024.
2
Sphingolipids: drivers of cardiac fibrosis and atrial fibrillation.鞘脂类:心脏纤维化和心房颤动的驱动因素。
J Mol Med (Berl). 2024 Feb;102(2):149-165. doi: 10.1007/s00109-023-02391-8. Epub 2023 Nov 28.
3
The Role of Sphingolipids in Regulating Vascular Permeability in Idiopathic Pulmonary Fibrosis.鞘脂在特发性肺纤维化中调节血管通透性的作用
Biomedicines. 2023 Jun 16;11(6):1728. doi: 10.3390/biomedicines11061728.
4
Sphingosine-1-Phosphate Signaling in Cardiovascular Diseases.鞘氨醇-1-磷酸信号通路在心血管疾病中的作用
Biomolecules. 2023 May 11;13(5):818. doi: 10.3390/biom13050818.
5
The Sphingosine 1-Phosphate Axis: an Emerging Therapeutic Opportunity for Endometriosis.鞘氨醇 1-磷酸轴:子宫内膜异位症的新兴治疗机会。
Reprod Sci. 2023 Jul;30(7):2040-2059. doi: 10.1007/s43032-023-01167-2. Epub 2023 Jan 20.
6
Sphk1 and Sphk2 Differentially Regulate Erythropoietin Synthesis in Mouse Renal Interstitial Fibroblast-like Cells.Sphk1 和 Sphk2 对小鼠肾间质成纤维细胞样细胞中促红细胞生成素合成的调控存在差异。
Int J Mol Sci. 2022 May 24;23(11):5882. doi: 10.3390/ijms23115882.
7
Sphingolipids in Lung Pathology in the Coronavirus Disease Era: A Review of Sphingolipid Involvement in the Pathogenesis of Lung Damage.冠状病毒病时代肺部病理学中的鞘脂:鞘脂参与肺损伤发病机制的综述
Front Physiol. 2021 Oct 8;12:760638. doi: 10.3389/fphys.2021.760638. eCollection 2021.
8
The role of sphingosine 1-phosphate and its receptors in cardiovascular diseases.鞘氨醇 1-磷酸及其受体在心血管疾病中的作用。
J Cell Mol Med. 2020 Sep;24(18):10290-10301. doi: 10.1111/jcmm.15744. Epub 2020 Aug 17.
9
Sphingosine-1-phosphate receptor-2 facilitates pulmonary fibrosis through potentiating IL-13 pathway in macrophages.鞘氨醇-1-磷酸受体-2 通过增强巨噬细胞中的 IL-13 通路促进肺纤维化。
PLoS One. 2018 May 21;13(5):e0197604. doi: 10.1371/journal.pone.0197604. eCollection 2018.
10
Sphingosine-1-phosphate pathway in renal fibrosis.鞘氨醇-1-磷酸途径在肾纤维化中的作用。
Am J Physiol Renal Physiol. 2018 Oct 1;315(4):F752-F756. doi: 10.1152/ajprenal.00596.2017. Epub 2018 Apr 4.

本文引用的文献

1
Cell migration activated by platelet-derived growth factor receptor is blocked by an inverse agonist of the sphingosine 1-phosphate receptor-1.
FASEB J. 2006 Mar;20(3):509-11. doi: 10.1096/fj.05-4810fje. Epub 2005 Nov 30.
2
The immunomodulator FTY720 and its phosphorylated derivative activate the Smad signalling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells.免疫调节剂FTY720及其磷酸化衍生物可激活Smad信号级联反应,并上调肾系膜细胞中结缔组织生长因子和IV型胶原的表达。
Br J Pharmacol. 2006 Jan;147(2):164-74. doi: 10.1038/sj.bjp.0706452.
3
Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses.1-磷酸鞘氨醇1型受体激动作用可抑制髓质T细胞经内皮迁移至淋巴窦。
Nat Immunol. 2005 Dec;6(12):1228-35. doi: 10.1038/ni1269. Epub 2005 Nov 6.
4
Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720.鞘氨醇激酶2型对于免疫调节药物FTY720诱导的淋巴细胞减少至关重要。
Blood. 2006 Feb 15;107(4):1454-8. doi: 10.1182/blood-2005-07-2628. Epub 2005 Oct 13.
5
Sphingosine 1-phosphate induces alpha-smooth muscle actin expression in lung fibroblasts via Rho-kinase.鞘氨醇-1-磷酸通过Rho激酶诱导肺成纤维细胞中α-平滑肌肌动蛋白的表达。
Kobe J Med Sci. 2005;51(1-2):17-27.
6
Scleroderma: from cell and molecular mechanisms to disease models.硬皮病:从细胞和分子机制到疾病模型
Trends Immunol. 2005 Nov;26(11):587-95. doi: 10.1016/j.it.2005.09.004. Epub 2005 Sep 15.
7
Essential roles of sphingosine-1-phosphate and platelet-derived growth factor in the maintenance of human embryonic stem cells.1-磷酸鞘氨醇和血小板衍生生长因子在维持人胚胎干细胞中的重要作用。
Stem Cells. 2005 Nov-Dec;23(10):1541-8. doi: 10.1634/stemcells.2004-0338. Epub 2005 Aug 4.
8
Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer.
J Med Chem. 2005 Aug 11;48(16):5373-7. doi: 10.1021/jm050242f.
9
Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy.实体器官移植中的免疫抑制剂:作用机制与治疗效果
Crit Rev Oncol Hematol. 2005 Oct;56(1):23-46. doi: 10.1016/j.critrevonc.2005.03.012.
10
FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation.新型免疫调节剂FTY720:首次肾移植2A期研究的疗效与安全性结果
Transplantation. 2005 Jun 15;79(11):1553-60.